Clinical Trials Logo

Stargardt Macular Dystrophy clinical trials

View clinical trials related to Stargardt Macular Dystrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT04239625 Enrolling by invitation - Stargardt Disease Clinical Trials

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Start date: December 20, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD

NCT ID: NCT02402660 Recruiting - Stargardt Disease Clinical Trials

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

TEASE
Start date: August 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD